serious infections (strong recommendation). An IL-12/23i or IL-17i biologic is recommended over a TNFi biologic (conditional recommendation [Table 6 Active PsA in patients requiring killed or live attenuated vaccinations when starting biologic treatment (Table 7). All recommendations for vaccinations in patients with active PsA are conditional based on very-low-quality evidence. It is recommended that the biologic treatment be started and the killed vaccines administered (as indicated based on